At the completion of the carefully designed preclinical and clinical studies, the drug's sponsor may file a _____
a) New Drug Application (NDA)
b) Investigational New Drug (IND) Application
c) Abbreviated New Drug Application (ANDA)
d) Biologics License Application (BLA)